- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
38
38 companies
Zevra Therapeutics
Market Cap: US$478.5m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$8.59
7D
-0.2%
1Y
8.1%
Axsome Therapeutics
Market Cap: US$9.1b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$183.30
7D
-0.5%
1Y
43.1%
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$26.61
7D
-1.0%
1Y
112.7%
Ardelyx
Market Cap: US$1.7b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.76
7D
-7.4%
1Y
5.3%
Pelthos Therapeutics
Market Cap: US$66.6m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$18.19
7D
-19.2%
1Y
2.2%
ARS Pharmaceuticals
Market Cap: US$874.8m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$9.38
7D
-5.4%
1Y
-20.3%
Madrigal Pharmaceuticals
Market Cap: US$10.6b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$487.32
7D
1.8%
1Y
43.4%
Capricor Therapeutics
Market Cap: US$1.2b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$23.03
7D
-6.5%
1Y
54.4%
Achieve Life Sciences
Market Cap: US$223.6m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.24
7D
-2.8%
1Y
28.9%
Corcept Therapeutics
Market Cap: US$4.2b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$39.63
7D
-2.9%
1Y
-46.1%
RenovoRx
Market Cap: US$35.9m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.98
7D
1.0%
1Y
-12.5%
Alnylam Pharmaceuticals
Market Cap: US$44.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$332.61
7D
3.2%
1Y
32.8%
Caris Life Sciences
Market Cap: US$5.8b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$20.80
7D
-6.2%
1Y
n/a
AC Immune
Market Cap: US$295.8m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.91
7D
-4.9%
1Y
10.2%
Kiniksa Pharmaceuticals International
Market Cap: US$3.4b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$45.38
7D
1.5%
1Y
132.1%
Eton Pharmaceuticals
Market Cap: US$457.8m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$17.15
7D
12.8%
1Y
0.1%
Longeveron
Market Cap: US$11.4m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.55
7D
-0.6%
1Y
-65.1%
Viridian Therapeutics
Market Cap: US$2.7b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$28.29
7D
-5.9%
1Y
70.6%
CollPlant Biotechnologies
Market Cap: US$9.1m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.63
7D
-4.9%
1Y
-82.3%
Belite Bio
Market Cap: US$6.6b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$175.84
7D
-0.6%
1Y
213.7%
Insmed
Market Cap: US$31.7b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$150.52
7D
1.3%
1Y
85.0%
SIGA Technologies
Market Cap: US$486.2m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.78
7D
1.3%
1Y
13.2%
BeOne Medicines
Market Cap: US$39.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$354.86
7D
1.0%
1Y
49.9%
Rhythm Pharmaceuticals
Market Cap: US$6.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$102.53
7D
4.1%
1Y
76.8%
Gyre Therapeutics
Market Cap: US$728.9m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$8.21
7D
3.0%
1Y
-35.4%
Journey Medical
Market Cap: US$257.1m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$8.10
7D
0%
1Y
57.6%
Earth Science Tech
Market Cap: US$37.9m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.13
7D
-12.8%
1Y
-27.8%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.30
7D
0%
1Y
45.2%
Benitec Biopharma
Market Cap: US$355.6m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$10.36
7D
-11.5%
1Y
-8.0%
Day One Biopharmaceuticals
Market Cap: US$1.2b
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$11.88
7D
4.0%
1Y
-0.4%
Fortress Biotech
Market Cap: US$112.0m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.50
7D
-6.7%
1Y
108.3%
Zymeworks
Market Cap: US$1.7b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$23.07
7D
1.1%
1Y
55.7%
Tarsus Pharmaceuticals
Market Cap: US$2.7b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$62.78
7D
-4.0%
1Y
26.7%
Protagonist Therapeutics
Market Cap: US$5.1b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$82.46
7D
-1.7%
1Y
118.4%
Geron
Market Cap: US$1.1b
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.80
7D
11.1%
1Y
-31.6%
Legend Biotech
Market Cap: US$3.2b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$18.11
7D
1.1%
1Y
-52.6%